Stephens Investment Management Group LLC Has $41.71 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Stephens Investment Management Group LLC trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 136,877 shares of the company's stock after selling 2,543 shares during the period. Stephens Investment Management Group LLC owned 0.48% of Medpace worth $41,705,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of MEDP. Invesco Ltd. lifted its stake in shares of Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after acquiring an additional 519,186 shares during the last quarter. Norges Bank bought a new position in shares of Medpace in the 4th quarter valued at $69,859,000. Fundsmith LLP bought a new position in shares of Medpace in the 4th quarter valued at $42,372,000. Spyglass Capital Management LLC lifted its stake in shares of Medpace by 85.1% in the 4th quarter. Spyglass Capital Management LLC now owns 262,660 shares of the company's stock valued at $87,264,000 after acquiring an additional 120,778 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Medpace by 31.3% in the 4th quarter. AQR Capital Management LLC now owns 480,186 shares of the company's stock valued at $159,532,000 after acquiring an additional 114,436 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 0.8%

Medpace stock traded down $2.53 during trading hours on Monday, reaching $320.97. 104,318 shares of the company's stock were exchanged, compared to its average volume of 411,683. The firm's 50 day simple moving average is $305.61 and its 200 day simple moving average is $318.52. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The firm has a market capitalization of $9.22 billion, a PE ratio of 24.50, a PEG ratio of 5.85 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 54.36% and a net margin of 19.31%. The firm had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period last year, the business posted $3.20 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

MEDP has been the subject of several analyst reports. Mizuho lowered their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Robert W. Baird lowered their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Truist Financial lowered their target price on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday, April 23rd. Finally, Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $344.82.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director directly owned 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 20.30% of the stock is currently owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.